Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 169

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 169
---
RA-300ACH and certain preclinical programs;

•$10.4 million increase in compensation and other personnel expenses, including an increase in stock-based compensation costs of  $6.0 million, driven by headcount growth; and

•$1.9 million increase in facilities and other operating costs due to our continuing expansion efforts.

General and Administrative Expenses 

General and administrative expenses were $24.1 million and $17.4 million for the years ended December 31, 2024 and 2023, respectively. The increase of $6.7 million was driven by: 

•$4.9 million increase in compensation and other personnel expenses, including an increase in stock-based compensation costs of $3.3 million, driven by headcount growth;

•$1.4 million increase in professional services, legal and other public company costs; and

•$0.4 million increase in facilities and other operating costs to support growing operations. 

Other Income

Other income was $17.7 million and $10.8 million for the years ended December 31, 2024 and 2023, respectively. The increase of $6.9 million was primarily related to an increase in our cash, cash equivalents and marketable securities balances due to proceeds received from our private placement completed in February 2024. 

Liquidity and Capital Resources

Sources of Liquidity 

On September 17, 2021, we completed our IPO and issued 12,420,000 shares of common stock for net proceeds of approximately $181.2 million. Prior to our IPO, we funded our operations primarily through private 

108

placements of our convertible preferred stock with net proceeds of $157.2 million, excluding issuance costs of $0.4 million. 

On February 6, 2024, we completed a private placement and issued 9,286,023 shares of our common stock and pre-funded warrants to purchase an aggregate of 6,087,230 shares of our common stock (the 2024 Private Placement) for net proceeds of approximately $199.6 million, excluding issuance costs of $0.4 million. 

On October 3, 2022, we entered into an ATM Sales Agreement (the Sales Agreement) with Virtu Americas LLC (the Agent), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $150.0 million in “at the market” offerings through the Agent. Sales of the shares of